Table 1.
Characteristics of the included studies on nonsteroidal anti-inflammatory drugs intake and prostate cancer
| First author | Published year | Study design | Country | Drugs | Study period | Information resource |
|---|---|---|---|---|---|---|
| Paganini-Hill [16] | 1989 | Cohort | USA | Aspirin | 1981 to 1988 | Questionnaire |
| Schreinemachers [22] | 1994 | Cohort | USA | Aspirin | 1971 to 1987 | Questionnaire |
| Neugut [31] | 1998 | Case-control | USA | Aspirin | 1984 to 1986 | Questionnaire |
| Norrish [38] | 1998 | Case-control | New Zealand | Aspirin, NA-NSAIDs, NSAIDs | 1996 | Questionnaire |
| Nelson [25] | 2000 | Case-control | USA | Aspirin, NA-NSAIDs | 1992 to 1995 | Questionnaire |
| Langman [34] | 2000 | Case-control | UK | NSAIDs | 1993 to 1995 | Database |
| Leitzmann [18] | 2002 | Cohort | USA | Aspirin | 1986 to 1998 | Questionnaire |
| Roberts [20] | 2002 | Cohort | USA | NSAIDs | 1990 to 1996 | Questionnaire |
| Habel [24] | 2002 | Cohort | USA | Aspirin | 1964 to 1996 | Questionnaire |
| Irani [35] | 2002 | Case-control | France | NA-NSAIDs | 1999 to 2000 | Questionnaire |
| Sorensen [19] | 2003 | Cohort | Denmark | NSAIDs | 1989 to 1995 | Database |
| Friis [29] | 2003 | Cohort | Denmark | Aspirin | 1989 to 1997 | Database |
| Perron [33] | 2003 | Cohort | Canada | Aspirin, NSAIDs | 1993 to 1996 | Database |
| Ratnasinghe [17] | 2004 | Cohort | USA | Aspirin | 1976 to 1992 | Questionnaire |
| García Rodríguez [36] | 2004 | Cohort | UK | Aspirin, NA-NSAIDs | 1995 to 2001 | Database |
| Jacobs [28] | 2005 | Cohort | USA | Aspirin, NA-NSAIDs, NSAIDs | 1992 to 2001 | Questionnaire |
| Platz [40] | 2005 | Cohort | USA | Aspirin, NA-NSAIDs | 1980 to 2004 | Questionnaire |
| Bosetti [21] | 2006 | Case-control | Italy | Aspirin | 1991 to 2002 | Questionnaire |
| Dasgupta [23] | 2006 | Case-control | Canada | Aspirin, NA-NSAIDs | 1999 to 2002 | Database |
| Mahmud [26] | 2006 | Case-control | Canada | Aspirin, NA-NSAIDs, NSAIDs | 1999 to 2003 | Questionnaire |
| Menezes [41] | 2006 | Case-control | USA | Aspirin, NA-NSAIDs | 1982 to 1998 | Questionnaire |
| Murad [32] | 2010 | Case-control | UK | Aspirin, NA-NSAIDs, NSAIDs | 2001 to 2008 | Database |
| Brasky [39] | 2010 | Cohort | USA | Aspirin, NA-NSAIDs | 2000 to 2007 | Questionnaire |
| Coogan [42] | 2010 | Case-control | USA | NSAIDs | 1992 to 2008 | Questionnaire |
| Salinas [43] | 2010 | Case-control | USA | Aspirin | 2002 to 2005 | Questionnaire |
| Dhillon [37] | 2011 | Cohort | USA | Aspirin | 1988 to 2006 | Questionnaire |
| Mahmud [44] | 2011 | Case-control | Canada | Aspirin, NA-NSAIDs, NSAIDs | 1985 to 2000 | Questionnaire |
| Shebl [30] | 2012 | Cohort | USA | Aspirin, NA-NSAIDs | 1993 to 2009 | Questionnaire |
| Veitonmaki [27] | 2013 | Case-control | Finland | Aspirin, NA-NSAIDs, NSAIDs | 1995 to 2002 | Database |
NA-NSAIDs, nonaspirin nonsteroidal anti-inflammatory drugs; NSAIDs, total nonsteroidal anti-inflammatory drugs.